Clomiphene QB http://clomipheneqb.com/ Tue, 02 Nov 2021 12:16:40 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://clomipheneqb.com/wp-content/uploads/2021/10/cropped-icon-32x32.png Clomiphene QB http://clomipheneqb.com/ 32 32 ??????? SHOP APOTHEKE EUROPE: TREATY OF THE FIRST ELECTRONIC PRESCRIPTION. https://clomipheneqb.com/shop-apotheke-europe-treaty-of-the-first-electronic-prescription/ https://clomipheneqb.com/shop-apotheke-europe-treaty-of-the-first-electronic-prescription/#respond Tue, 02 Nov 2021 05:47:02 +0000 https://clomipheneqb.com/shop-apotheke-europe-treaty-of-the-first-electronic-prescription/ DGAP-News: SHOP APOTHEKE EUROPE NV / Keyword (s): Miscellaneous

??????? SHOP APOTHEKE EUROPE: TREATY OF THE FIRST ELECTRONIC PRESCRIPTION.

02.11.2021 / 06:45
The issuer is solely responsible for the content of this advertisement.

SHOP APOTHEKE EUROPE: TREATY OF THE FIRST ELECTRONIC PRESCRIPTION.

November 2, 2021. The first real electronic prescriptions have been received and successfully processed by SHOP APOTHEKE EUROPE. This important step in the history of the company was taken on Thursday, October 28, when the first real electronic prescription arrived.

SHOP APOTHEK EUROPE has been preparing for the introduction of electronic prescribing (e-Rx) for over two years and has been ready since this summer. The processing of the first e-Rx demonstrates that all front-end and back-end processes of SHOP APOTHEKE EUROPE are functioning correctly. The gematik e-Rx pilot project in Germany started in July in the concentration region of Berlin-Brandenburg.

After an intense preparation phase, SHOP APOTHEKE EUROPE has now demonstrated that the company is ready to manage electronic prescriptions. “This is a great success for our project team and our company as a whole. We have been working at this exciting time for over two years,” said Stefan Feltens, CEO. “As the leading German brand of online pharmacies, with our commitment to improving the lives of our patients, we are uniquely positioned to provide even better service to our prescription drug customers. “

After the ongoing pilot phase and a nationwide introduction phase in December, electronic prescriptions are expected to become mandatory for all medicines prescribed to people covered by statutory insurance in Germany from January 1, 2022 or later. this year. Patients based in Germany will then be able to submit their prescriptions directly in the online store or via the SHOP APOTHEKE app.

SHOP APOTHEKE EUROPE customers will continue to be able to send a paper prescription via regular mail – so patients can choose the method that best suits their needs. However, SHOP APOTHEKE EUROPE expects e-prescriptions to become the norm in Germany after the launch phase: “We expect our customers to quickly adopt e-prescriptions and the convenience they offer. Digital services are now a part of the lives of all age groups and we are excited to finally be able to offer our customers this safe and fast way to fill their prescriptions, ”said Stephan Weber, Chief Commercial Officer and Co-Founder.

ABOUT THE APOTHEKE EUROPE STORE.
SHOP APOTHEKE EUROPE is one of the leading and fastest growing online pharmacies in Europe, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Based in the Dutch logistics hub of Sevenum near Venlo with establishments in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Paris and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a wide range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality food and natural health products, low carbohydrate products and sports nutrition. Currently, more than 7 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice is a top priority at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical advice services.

Ahead of the introduction of electronic prescriptions in Germany in the summer of 2021, the company will further enhance the customer experience by focusing on digital disease-specific drug management services following the acquisition of SMARTPATIENT in January 2021 This is a key part of SHOP APOTHEKE EUROPE strategy to transform from a simple online retailer into a truly customer-centric electronic pharmacy platform.

SHOP APOTHEKE EUROPE NV has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.

PRESS CONTACT.

Commerce and popular media:
Sven Schirmer
Phone: +49 221 99 53 44 31
Email: presse@shop-apotheke.com

Financial media:
Bettina Fries
Phone: +49 211 75 80 779
Email: presse@shop-apotheke.com

Investor Relations:
Carmen Herkenrath
Phone. : +31 77 850 6109
Email: carmen.herkenrath@shop-apotheke.com

Thomas Schnorrenberg
Mobile: +49 151 465 31317
Email: presse@shop-apotheke.com

02.11.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this advertisement.

DGAP’s distribution services include regulatory announcements, financial / corporate news, and press releases.
Archives on www.dgap.de

Source link

]]>
https://clomipheneqb.com/shop-apotheke-europe-treaty-of-the-first-electronic-prescription/feed/ 0
How OTC brands can find opportunities in the doctor’s office https://clomipheneqb.com/how-otc-brands-can-find-opportunities-in-the-doctors-office/ https://clomipheneqb.com/how-otc-brands-can-find-opportunities-in-the-doctors-office/#respond Mon, 01 Nov 2021 17:07:00 +0000 https://clomipheneqb.com/how-otc-brands-can-find-opportunities-in-the-doctors-office/

You might not realize it, but Tom Finn is in your medicine cabinet. The former president of P & G’s global personal health care business is one of the most experienced and distinguished marketers in consumer health.

With consumer interest in health booming, today there are incredible opportunities for over-the-counter (OTC) marketers to generate significant growth for their brands, but only if they look in the right places. . I sat down with Tom to hear his take on this growth potential and the innovative strategies all marketers should include in their plans.

Linda Ruschau: You have contributed to significant growth in the consumer healthcare market during your time at P&G. Is this level of growth sustainable today?

Tom Finn: I am often asked this question. I believe the consumer healthcare market can and will maintain strong growth for years to come, but only if marketers are prepared to embrace innovative tactics beyond traditional means. During my 13 year tenure as the head of Procter & Gamble’s global OTC business, we have seen the consumer healthcare market grow by 4-5% per year, and I believe it can continue to grow. do so for the foreseeable future.

Ruschau: Build a little more on it. What do you mean by “innovative tactics”?

Finnish: When I say innovative, I don’t necessarily mean new. There are some high-performing tactics that have been around for decades and remain largely underutilized by mainstream health marketers today. A good example is getting the referral from the healthcare professional. In my opinion, this is the most effective and sustainable way to attract new consumers to a healthcare market. It makes sense that a healthcare professional with intimate knowledge of the health condition and medical needs of their patients would be in the best position to connect people with consumer healthcare solutions. It’s a tactic I’ve used for many of my P&G brands, but I’m still surprised that not all marketers capitalize on the value it offers.

Ruschau: Thanks to the pandemic, the access of OTC marketers to healthcare professionals has become even more restricted and prohibitive. How can marketers effectively reach these professionals for a recommendation?

Finnish: I agree – today it’s hard to replicate the pro-driven success models of brands like Advil, Tylenol, Flonase or PreserVision, to name a few. Few mainstream healthcare companies have access to or can afford a large sales force or to offer vendor details i.e. visits to healthcare practices to educate physicians or make prescriptions available to them to offer as treatments to their patients. It’s harder than ever to have time with healthcare professionals, and it’s also difficult and / or expensive to identify and target consumers with specific health concerns through digital or social media approaches. Good luck trying to outbid an Rx company for popular search terms like diabetes, arthritis, or irritable bowel syndrome (IBS).

Another way to cultivate professional endorsement of consumer health solutions is through the use of physician office or “point of care” engagement solutions. Consider the educational and awareness video tools featured in doctor’s office waiting rooms, examination rooms, and in the back office.

Having an office presence allows you to reach your target consumers with a specific and highly valuable message at a time when information is extremely relevant and a priority for them. Your post can empower them to take action by asking healthcare providers or their staff about the value of a product and ultimately buying it. On the other hand, most doctors and nurses take the time to be aware of the information presented to patients in their offices and examination rooms. So, with these cabinet engagement programs, you can reach and influence healthcare professionals without detailing them.

In addition, these engagement programs can help achieve and maintain the most important goals. Physician Recommended Claim # 1 is used on packaging and in advertisements. In my experience, I have always found that the use of a product initiated by a doctorThis recommendation was much stronger and much more durable than the usage generated strictly by mainstream advertising or public relations.

Ruschau: Which segments of the consumer healthcare market can benefit the most from a growth engine of professional referral?

Finnish: All! There is significant growth potential in all major segments of the consumer health market, whether it is the treatment of acute conditions, self-management of chronic conditions, or the improvement, prevention segment. and well-being.

There is also significant growth potential in encouraging consumers with chronic conditions to use over-the-counter products earlier in their treatment as well as throughout the course of treatment, as many still commit too late or at a dose and / or a sub-optimal duration.

Ruschau: One final tip for consumer health marketers today?

Finnish: For most of my career, I pushed the consumer health marketers who worked for me to identify, target, and cultivate new users of their products, not just focus on market share. I believe the potential for market expansion remains immense in almost all segments of consumer health, and the benefits we could and should provide to consumers remain significant and important. We can expand all of our consumer health segments by simply educating consumers and their influencers about the potential uses, proven benefits, and proper administration of our existing products and regimens.

My other long-standing tip for consumer health marketers is to harness and cultivate the unique and enduring power of professional training and referrals. Although underutilized, it remains the most proven, effective and sustainable method for expanding consumer health categories.

For more information from Tom Finn, download the white paper “An Untapped Strategy for Sustainable Brand Growth: The Value of Professional Recommendations”.

Source link

]]>
https://clomipheneqb.com/how-otc-brands-can-find-opportunities-in-the-doctors-office/feed/ 0
Essity acquires sports tape brands from Johnson & Johnson Consumer Inc. https://clomipheneqb.com/essity-acquires-sports-tape-brands-from-johnson-johnson-consumer-inc/ https://clomipheneqb.com/essity-acquires-sports-tape-brands-from-johnson-johnson-consumer-inc/#respond Mon, 01 Nov 2021 07:32:00 +0000 https://clomipheneqb.com/essity-acquires-sports-tape-brands-from-johnson-johnson-consumer-inc/

STOCKHOLM, November 1, 2021 / PRNewswire / – Hygiene and health company Essity has acquired the Coach, Elastikon and Zonas professional sports tape brands from Johnson & Johnson Consumer Inc., which are high-end products well established in the US market. Essity is a world leader in the adhesive tape and strapping market and following the acquisition, the company will also become a leader among US sports drug distributors. The purchase price is not significant relative to Essity’s market capitalization and is not disclosed.

Coach, Elastikon and Zonas are three highly respected brands in the US market. The products are mainly sold through sports medicine distributors to schools, sports clubs and professional sports teams. The brands have a strong reputation and are considered high-end products in the world of sport. Elastikon is produced by Essity and Coach and Zonas will be added to in-house production in the future.

“Growth through acquisitions in Medical Solutions is a key strategic priority. The US tape and strapping market is the largest in the world, and Essity is now taking a larger share of that market. The acquisition of the Johnson & Johnson ‘Consumer Inc sports tape brands will make Essity the leader in duct tape and strapping among US sports drug distributors. The acquisition also opens up opportunities for our existing product line, ”says Ulrika Kolsrud, President of Healthcare and Medical Solutions, Essity.

Coach, Elastikon and Zonas will be part of Essity’s Medical Solutions business, which provides innovative and high-quality medical products and solutions in the fields of compression, wound care and orthopedics. With global brands such as Leukoplast, JOBST, Cutimed, Actimove and Delta-Cast, Essity holds strong market positions in many therapeutic areas.

For more information, please contact:
Karl Stoltz, Press Relations Manager, +46 8 788 51 55
Johan karlsson, Vice-President Investor Relations, +46 8 788 51 30

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/essity/r/essity-acquires-sports-tape-brands-from-johnson—johnson-consumer-inc-,c3444181

The following files are available for download:

SOURCE Essity

Source link

]]>
https://clomipheneqb.com/essity-acquires-sports-tape-brands-from-johnson-johnson-consumer-inc/feed/ 0
Chronic Pain, Opioid Prescription Law Changes Subject Of Online Streaming Legislative Study Monday | Government-and-politics https://clomipheneqb.com/chronic-pain-opioid-prescription-law-changes-subject-of-online-streaming-legislative-study-monday-government-and-politics/ https://clomipheneqb.com/chronic-pain-opioid-prescription-law-changes-subject-of-online-streaming-legislative-study-monday-government-and-politics/#respond Mon, 01 Nov 2021 05:00:00 +0000 https://clomipheneqb.com/chronic-pain-opioid-prescription-law-changes-subject-of-online-streaming-legislative-study-monday-government-and-politics/

At the time, CDC data ranked Oklahoma 6th in the country for opioid prescriptions dispensed per capita.

Stewart is now the Policy Director of P3Alliance, whose mission is to protect patients by raising awareness of “accurate and politically neutral information on the opioid crisis.” She has become an activist herself as a chronic pain sufferer. A two-time cancer survivor, she has undergone more than a dozen surgeries.

Support local journalism

Your subscription makes our reporting possible.

{{featured_button_text}}

SB1446 started to affect him before it became law, when his pain management doctor cut his medication.

“It’s an environment where everyone is afraid to write prescriptions because of the stigma,” Stewart said in an interview with Tulsa World in 2018.

Tally said a voter approached her asking for the study “to get honest answers” on safe and effective opioid prescriptions.

“Come and find out that there are people who need opioids to do it every day,” he said, adding that he knows the lawmakers who need daily pain management. small amounts.

Of course, with any drug comes the potential for harmful use, and Tally said it’s important to weed out bad actors “claiming a toothache so they can get 50 pills.”

Source link

]]>
https://clomipheneqb.com/chronic-pain-opioid-prescription-law-changes-subject-of-online-streaming-legislative-study-monday-government-and-politics/feed/ 0
Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd, Sanofi – The host https://clomipheneqb.com/novartis-ag-pfizer-inc-f-hoffmann-la-roche-ltd-sanofi-the-host/ https://clomipheneqb.com/novartis-ag-pfizer-inc-f-hoffmann-la-roche-ltd-sanofi-the-host/#respond Sun, 31 Oct 2021 05:22:33 +0000 https://clomipheneqb.com/novartis-ag-pfizer-inc-f-hoffmann-la-roche-ltd-sanofi-the-host/

Introduction and scope
Comprehensive approach applied to prescription drug market analysis delivering valuable insight as well as factual evidence and actionable insights to client base consisting of commercial investors, stakeholders, venture capitalists and entrepreneurs. The study compiles an array of data derived from in-depth, organic research crossing the critical complexities of the prescription drug market. The data offered in the market report is structurally organized and relevant to the industry, which represents an unbiased, decisive, and authentic report on the Keyword Market. The study deliverables encompass strategic perspective, revenue scales and models, industry valuations, demand-supply ratio, and cost structure of the Prescription Drugs market.

Landscape and supplier profiling:
Novartis AG
Pfizer, Inc.
F. Hoffmann-La Roche Ltée
Sanofi
Johnson and Johnson Services, Inc
Merck and Co., Inc.
AbbVie, Inc.
GlaxoSmithKline plc.
AstraZeneca
Bristol-Myers Squibb Company

We have recent updates of the prescription drug market in the sample [email protected] https://www.orbisresearch.com/contacts/request-sample/6151586?utm_source=PoojaAD6

The study deliverables emphatically presents the growth-inducing variables and their impact pathway to accelerate the growth of the Prescription Drug Market. Along with the growth stimulators, the market research describes the range of factors effectively hampering the growth of the market directly or indirectly. The fluctuations in growth observed in the current state of the prescription drug market are effectively explained by the prevalence of recognized growth modifying factors. It also helps to estimate the possible opportunistic landscape describing the growth prospects as well as the potential emergence of challenges facing the prescription drug market.

Market segmentation: prescription drug market

Product-based segmentation:
By type of product (generics, orphans, others); Therapy (Oncology, Antidiabetics, Vaccines, Sensory Organs, Immunosuppressants, Anticoagulants, Others); Distribution channel (hospital pharmacies, online pharmacies, retail pharmacies and pharmacies),

Segmentation based on applications:
Application I, Application II, Application III

Browse Complete Report With Facts & Figures Of The Prescription Drugs Market Report At @ https://www.orbisresearch.com/reports/index/prescription-medicines-market-2021-2028-emerging-growth-factors-trends-leading-players-and-in-depth-segmentation?utm_source=PoojaAD6

In addition, Growth Influencers, the study report also provides insightful assessment of key trends influencing the growth and opportunities for the Prescription Drug market including industrial, non-industrial, economic, or demographic trends. In addition, technological megatrends are also assessed for their impact on modernizing the prescription drug market. emerging market trends are assessed alongside current events around the world, such as the significant shift in business strategies following the onset of COVID-19, assessing the short and long term trends that have been defined by the pandemic, accelerating a substantial change in prescription. Dynamics of the drug market.

Regional assessment and diversification of segments.

North America (United States, Canada, Mexico)
Europe (UK, France, Germany, Spain, Italy, Central and Eastern Europe, CIS)
Asia Pacific (China, Japan, South Korea, ASEAN, India, rest of Asia-Pacific)
Latin America (Brazil, rest of LA)
Middle East and Africa (Turkey, CCG, Rest of Middle East)

By adding the conclusive research results, the market study targets major players at the epicenter of the prescription drug market with market dominance and historical significance. The major prominent manufacturers of the prescription drug market are identified and further studied by assessing their main strengths and challenges. The study incorporates specific initiatives implemented to adapt to modernization trends in the industry, including the integration of new strategic concepts and the adoption of advanced technological systems to maximize productivity and ultimately , fueling the growth of the overall prescription drug market. The study highlights the latest industry events such as mergers and acquisitions of key importance in driving the growth of the market.

Highlights of the report
• The report includes country-specific growth projections for the prescription drug industry over the next five years.
• Prescription drug products or services at the region level request data.
• Regional information on the prescription drug market.
• Market share overview.
• Application and product information including revenue in millions of dollars from 2015 to 2025.
• Supply and demand analyzes are provided in the report.
• Value chain analysis and stakeholder analysis are provided in the study.
• The report covers major geographies including Eastern Europe, Western Europe, North America, Middle East, Africa and Asia Pacific.

Apply before purchase @ https://www.orbisresearch.com/contacts/enquiry-before-buying/6151586?utm_source=PoojaAD6

About Us:
Orbis Research (orbisresearch.com) is a one-stop shop for all of your market research needs. We have a large database of reports from leading publishers and authors around the world. We specialize in providing personalized reports according to the requirements of our clients. We have complete information about our publishers and are therefore confident of the correctness of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect market research required for our clients.

Contact us:
Hector Costello
Senior Manager Client Engagement
Central highway 4144N,
Office 600, Dallas,
Texas 75204, United States
Phone number: United States: +1 (972) -362-8199 | IND: +91 895 659 5155

Source link

]]>
https://clomipheneqb.com/novartis-ag-pfizer-inc-f-hoffmann-la-roche-ltd-sanofi-the-host/feed/ 0
The future of brands lies in handing over control to consumers https://clomipheneqb.com/the-future-of-brands-lies-in-handing-over-control-to-consumers/ https://clomipheneqb.com/the-future-of-brands-lies-in-handing-over-control-to-consumers/#respond Sat, 30 Oct 2021 09:55:00 +0000 https://clomipheneqb.com/the-future-of-brands-lies-in-handing-over-control-to-consumers/

New Delhi [India], Oct. 30 (ANI / NewsView): BASES, a NielsenIQ company, has released the winners of the highly anticipated 2021 ‘BASES Top Breakthrough Innovations’ awards, its annual list of successful innovations by brands across India as well as exclusive details devoting the strategies of the winners and how they conceived the brilliant ideas.

NielsenIQ BASES is a leader in helping businesses build brands through innovation, renovation, strategy and go-to-market optimization, and is a trusted partner at scale global and in all sectors. BASES helps maximize end-to-end brand success through advanced predictive analytics, behavioral science, proprietary databases, expert advice, and agile digital technology platforms.

NielsenIQ BASES uses different evaluation criteria for innovations aimed at mass consumption versus those aimed at a niche audience. It varies depending on whether the goal is to generate long-term vs. short-term income gain, increase the category pie, gain share within the category, or simply avoid competitive pressure. NielsenIQ BASES reviewed innovations in 100 categories with a minimum 18-month market presence in FMCG (Fast Moving Consumer Goods) OTC (Over the Counter).

“When evaluating innovations, there is no longer a ‘one size fits all’ approach. It is crucial to know the objectives and the innovation strategy of the company. A key factor to consider is the strength of the innovation over time, in line with revenue targets and other criteria. In the post-pandemic era, Indian consumers have become health conscious and have changed their choices to be more environmentally friendly, this trend is visible in all product categories ”, said Vidya Sen, Asia Manager South, NielsenIQ BASES.

It’s October 2021, but COVID-19 is still a concern in growing and developing markets like India: 9 in 10 Indian respondents to BASES survey express concern about COVID -19 and 80% of Indians consider hygiene products more important today than before the pandemic. COVID-19 has only increased the sense of health hygiene awareness and concern for the environment while reducing mobility. The innovations that have been on the “Best Breakthrough Innovations” list are keenly aware of this shift in consumer behavior, and healthy, natural and sustainable products are at the heart of their product offerings.

Breakthrough Innovations seized the innovation opportunity through various strategies. Some winners came up with natural or local ingredients, such as Himalaya Pure Hands Hand Wash, Colgatereg, ZigZag Neem, Oral-B Shiny Clean with Clove Extract, and Good Knight Naturals Neem Agarbatti. Others have been successful through health and immunity platforms – like STAYFIT ORSFIT, fortified with vitamins for better health, and Sunfeast Veda Marie Light, built on the health property of Ayurveda. Wowpertrade; Fresh PANTS has won over consumers with a “local brand” positioning that is personal and within reach. Keventer Dairy has targeted eastern and northeastern India and made good quality milk available to these consumers. Convenience was the road to success for Godrej Expert Easy 5 Minute Hair Color Shampoo.

Adding spice and festivity with their new flavors has made Red Bull Orange, Red Bull Coconut Twist and Cadbury Dairy Milk Very Strawberry drinks among the top innovations.

As an extension of its consultancy work, NielsenIQ BASES has identified a host of exciting future trends among consumers in India. These include: Technology – a key catalyst for innovation, Convenience and easy access will be deciding factors, Consumers value honesty and transparency, Kindness to Mother Earth is valued, and last but not least – Health is the new “wealth”.

“Natural ingredients”, “honesty and transparency” Organic has become a popular choice specifically for Indians, compared to other markets. Clean ingredient lines and locally grown ingredients are among the top two common choices impacting confidence, innovation and premium look for Indian consumers. Additionally, consumers now want greater transparency when it comes to their food, especially in understanding what ingredients go into those products, as well as where and how the food is grown or manufactured. 90% of Indian consumers place more emphasis on transparency, due to the impact their food choices will have on their personal health.

“By focusing on the ingredients in the product, brands give consumers the feeling that the product is made with quality ingredients. If there are pro-health nutrients with proven benefits, brands should consider incorporating these facts into the package label. Consumers are looking for easier ways to link the foods they eat to health benefits, but are not sufficiently informed about specific ingredient / nutrient relationships to make the connection themselves, ”said Vidya.

Health is the new ‘wealth’ A BASES study found that Indians want their drinks to be healthy (56%), nutritious (68%) and taste good (83%). As Indian consumers increasingly seek holistic health benefits, they claim to favor sophisticated ingredients such as plant protein, magnesium, collagen, electrolytes, and creatine to create fortified drinks.

“Consumers perceive current offers as insufficient when it comes to nutrition. They offer taste and convenience, but they have the potential to improve their health quotient. Energy drinks and immunity boosting are finding favor in India. From an ingredient perspective, probiotics, herbal, and organic ingredients are sought after by Indian consumers. While innovating in healthcare, brands need to keep taste and affordability in mind, ”Vidya said.

Caring for Mother Earth, with Sustainable Packaging As consumers become more environmentally conscious, they are also more concerned about the environmental impact of brands’ packaging choices. Research results show that excessive wastage of packaging is the number one concern of Indians when it comes to consuming beverages, followed by unsanitary conditions. Indians are more open to biodegradable packaging followed by refillable / multi-purpose packaging types.

Technology is a key tool Consumers seek much more control when making purchasing decisions and the COVID-19 pandemic has further reinforced this attitude – paving the way for a digital revolution. Claimed use of online services for personal care, food and OTC has indeed increased by 65%, 45% and 78% respectively. Following this buying trend, Indian consumers are also generally receptive to trying technology-based personal care solutions, such as facial scoring and smart electrical devices.

“The use of technology is redefining our expectations for customer service and purchasing high quality products. Consumers are looking for more personalization and COVID has disrupted the way we shop. The ability to customize products based on the unique needs of consumers will be a differentiator for brands. , especially in cosmetics, hair and facial skin care, ”Vidya said.

Convenience and Access A growing number of Indians are using online pharmacies and mobile apps for more convenient interactions at home. 60% of Indians are much more comfortable buying medicine from an online pharmacy than 5 years ago and 66% are currently using a health app on their phone or computer.

For more information, NielsenIQ is the leader in providing the most comprehensive and unbiased view of consumer behavior, on a global scale. Powered by a revolutionary consumer data platform and powered by rich analytics capabilities, NielsenIQ enables bold and confident decision making for the world’s leading consumer goods companies and retailers.

By using comprehensive data sets and measuring all transactions equally, NielsenIQ provides customers with a forward-looking view of consumer behavior to optimize performance across all retail platforms. Our open philosophy of data integration results in the most influential consumer data sets on the planet. NielsenIQ provides the full truth.

NielsenIQ, an Advent International portfolio company, operates in nearly 100 markets, covering over 90% of the world’s population.

For more information, please visit This story is provided by NewsView. ANI will not be responsible for the content of this article in any way. (ANI / NewsView)

Source link

]]>
https://clomipheneqb.com/the-future-of-brands-lies-in-handing-over-control-to-consumers/feed/ 0
West Vancouver residents targeted by prescription drug scam https://clomipheneqb.com/west-vancouver-residents-targeted-by-prescription-drug-scam/ https://clomipheneqb.com/west-vancouver-residents-targeted-by-prescription-drug-scam/#respond Fri, 29 Oct 2021 14:05:00 +0000 https://clomipheneqb.com/west-vancouver-residents-targeted-by-prescription-drug-scam/

West Vancouver Police say they have seen a series of reports of a new type of scam targeting people who take prescription drugs.

The fraud involves a person cold calling residents of West Vancouver, pretending to be from a local pharmacy and claiming their script has been completed. They just need a credit card number to process it, go.

“Over the past week, we’ve received about 30 calls regarding the exact same scam. They are only those who chose to call the police on this matter. There are probably a lot more, ”said Const. West Vancouver Police spokesperson Kevin Goodmurphy. “They guess. They’re hoping someone has a standing order with a local pharmacy. Enough people doing this, it wouldn’t be strange for a lot of people to get that call.

Taking the scam a step further, the appellant sometimes offered home delivery of the drugs, which requires the victim to hand over their home address, another personal information that can be used in identity theft.

Goodmurphy said he was proud of the people who sensed the trouble and alerted West Vancouver police, although he added that he was aware of at least two cases of crooks making illegal purchases with stolen credit card information. Fortunately, these are relatively small amounts.

These days, Goodmurphy said, it’s good to be wary of divulging personal information over the phone. If in doubt, hang up and verify the number so you can call yourself back or venture there in person, he said.

“It’s pretty reasonable to think that your pharmacy wouldn’t necessarily call and look for credit card information,” he said.

Source link

]]>
https://clomipheneqb.com/west-vancouver-residents-targeted-by-prescription-drug-scam/feed/ 0
In-Depth Research on Regenerative Medicine Products Market Forecast – Estimate and Approach 2021-2026 | Acelity, DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Organogenesis, etc. https://clomipheneqb.com/in-depth-research-on-regenerative-medicine-products-market-forecast-estimate-and-approach-2021-2026-acelity-depuy-synthes-medtronic-zimmerbiomet-stryker-organogenesis-etc/ https://clomipheneqb.com/in-depth-research-on-regenerative-medicine-products-market-forecast-estimate-and-approach-2021-2026-acelity-depuy-synthes-medtronic-zimmerbiomet-stryker-organogenesis-etc/#respond Thu, 28 Oct 2021 19:38:35 +0000 https://clomipheneqb.com/in-depth-research-on-regenerative-medicine-products-market-forecast-estimate-and-approach-2021-2026-acelity-depuy-synthes-medtronic-zimmerbiomet-stryker-organogenesis-etc/

Regenerative Medicine Products market report provides detailed analysis of global market size, regional and country level market size, market segmentation growth, market share, competitive landscape, analysis of sales, impact of national and global market players such as Acelity, DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Organogenesis, etc., value chain optimization, business regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, regional market expansion and innovations technological.

The key areas that have been targeted in the report:

  • Main trends observed in the global regenerative medicine products market
  • Market and price issues
  • Extent of commerciality in the market
  • Geographical limits
  • Distribution, planning, performance and supplier requirements
  • Growth opportunities that may emerge in the industry in the years to come
  • Growth strategies envisaged by the players.

Get Exclusive Sample Of Regenerative Medicine Products Market Report @ https://www.affluencemarketreports.com/industry-analysis/request-sample/1813 Regenerative Medicine Products /

Regenerative Medicine Products Market Segmentation:

The Regenerative Medicine Products market is segmented by Type and by Application. For the period 2016-2026, the growth among the segments provides accurate sales calculations and forecasts by type and by application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

Regenerative Medicine Products Market report on the basis of Product Type:

  • Cell therapy
  • Fabric creation
  • Biomaterial
  • Others

Regenerative Medicine Products Market Report Based On Applications:

  • Dermatology
  • Cardiovascular
  • SNC
  • Orthopedic
  • Others

The major players in the global regenerative medicine products market are listed below:

  • Acelity
  • DePuy Synthes
  • Medtronic
  • ZimmerBiomet
  • Stryker
  • MiMedx Group
  • Organogenesis
  • UniQure
  • International Cell Dynamics
  • Osiris Therapeutics
  • Vcanbio
  • Gamida cell
  • Gold meditated
  • Therapeutic cytori
  • Celgene
  • Vericel Corporation
  • Guanhao Biotech
  • mesoblast
  • Stem cell technologies
  • Bellicum Pharmaceuticals

Get Additional Discount on Regenerative Medicine Products Market Report, If your business is listed in the list of key players above @ https://www.affluencemarketreports.com/industry-analysis/request-discount/1813 Regenerative Medicine Products /

Promising Regions & Countries Mentioned In The Regenerative Medicine Products Market Report:

  • North America [United States, Canada, Mexico]
  • South America [Brazil, Argentina, Columbia, Chile, Peru]
  • Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
  • Middle East and Africa [GCC, North Africa, South Africa]
  • Asia Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

TABLE OF CONTENTS INCLUDES

Consumption forecast, market opportunities and challenges, risk and influencing factors analysis, market size by application, market size by manufacturers, market size by type, regenerative medicine products consumption by regions, product production Regenerative Medicine Products by Regions, Production Forecast, Value Chain and Sales Channel Analysis, Global Regenerative Medicine Products Global Study Main Findings, Manufacturer Profiles

Customization of the report: Customers can request customization of the report according to their need for additional data.

CONTACT FOR ADDITIONAL CUSTOMIZATION @ https://www.affluencemarketreports.com/industry-analysis/request-inquiry/1813 Regenerative Medicine Products /

  1. Regenerative Medicine Products Market Overview
  2. Company Profiles: Acelity, DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, MiMedx Group, Organogenèse, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori Therapeutics, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblem Médaments,
  3. Sales of regenerative medicine products by major players
  4. Regenerative Medicine Products Market Analysis by Region
  5. Regenerative Medicine Products Market Segmentation By Type: Cell therapy, Tissue engineering, Biomaterial, Others
  6. Regenerative Medicine Products Market Segmentation By Application: Dermatology, Cardiovascular, CNS, Orthopedic, Others
  7. North America by Country, Type and Application
  8. Europe by country, type and application
  9. Asia-Pacific by Country, Type and Application
  10. South America by Country, Type and Application
  11. Middle East & Africa by Country, Type and Application
  12. Sales channel, distributors, traders and resellers
  13. Research findings and conclusion
  14. Annex

Impact of COVID-19 on the Regenerative Medicine Product Market

The report also contains the effect of the ongoing global pandemic i.e. COVID-19 on the Regenerative Medicine Products market and what the future holds for it. It offers an analysis of the impacts of the epidemic on the international market. The epidemic immediately interrupted the series of needs and supplies. The Regenerative Medicine Products market report also assesses the economic effect on businesses and money markets. Futuristic Reports has amassed the advice of several delegates from this company and has engaged from secondary and primary research to extend strategies and data to clients to combat industry challenges during and after the COVID pandemic. -19.

For more details on the impact of COVID-19 on the regenerative medicine products market https://www.affluencemarketreports.com/industry-analysis/covid19-request/1813 Regenerative Medicine Products /

Frequently Asked Questions

  • What is the scope of the Regenerative Medicine Products market report?
  • Does this report estimate the current market size for Regenerative Medicine Products?
  • Does the report provide the Regenerative Medicine Products market size in terms of – value (Million USD) and volume (Thousands of units) – of the market?
  • What segments are covered in this report?
  • What are the key factors covered in this Regenerative Medicine Products market report?
  • Does this report offer customization?

About wealth:

Affluence Market Reports is the next generation of all your research needs with a strong struggle in the global marketplace for industries, organizations and governments. Our goal is to provide exemplary reports that meet specific client needs, which provide the right business technique, planning and competitive landscape for new and existing industries that will develop your business needs.

We offer a superior, in-depth statistical approach, a 360-degree view of the market that includes detailed segmentation, key trends, strategic recommendations, growth figures, cost analysis, new advancements, evolving technologies and forecasts from authentic agencies.

For more details, contact us:

Attendance Market Reports

Contact: Mr. Rohit

Phone number:

United States: + 1- (424) 256-1722

UK: +44 1158 88 1333

E-mail: [email protected]

Website: www.affluencemarketreports.com

Source link

]]>
https://clomipheneqb.com/in-depth-research-on-regenerative-medicine-products-market-forecast-estimate-and-approach-2021-2026-acelity-depuy-synthes-medtronic-zimmerbiomet-stryker-organogenesis-etc/feed/ 0
Prestige Brands (PBH) Profits Expected to Increase: Should You Buy? https://clomipheneqb.com/prestige-brands-pbh-profits-expected-to-increase-should-you-buy/ https://clomipheneqb.com/prestige-brands-pbh-profits-expected-to-increase-should-you-buy/#respond Thu, 28 Oct 2021 19:05:20 +0000 https://clomipheneqb.com/prestige-brands-pbh-profits-expected-to-increase-should-you-buy/

Wall Street expects year-over-year profit growth on higher revenues when Prestige Brands (PBH) reports results for the quarter ended September 2021. While this widely known consensus outlook is important In assessing a company’s earnings position, a powerful factor that could affect its stock price in the short term is how actual results compare to those estimates.

The earnings report, which is expected to be released on November 4, 2021, could help the stock rise if those key numbers are better than expectations. On the other hand, if they run out, the stock may go down.

While the sustainability of the immediate price change and future profit expectations will primarily depend on management’s discussion of trading conditions when calling profits, it is worth crippling the likelihood of a positive surprise from the market. BPA.

Zacks consensus estimate

This drug distributor is expected to post quarterly earnings of $ 0.99 per share in its next report, which represents a year-over-year change of + 26.9%.

Revenue is expected to reach $ 261.29 million, up 10.1% from the previous year quarter.

Trend of estimated revisions

The consensus EPS estimate for the quarter has remained unchanged over the past 30 days. This essentially reflects how hedge analysts collectively reassessed their initial estimates during this time period.

Investors should be aware that an overall change may not always reflect the direction of estimate revisions by individual hedge analysts.

Price, consensus and EPS Surprise

Whisper of gains

Revisions to estimates before a company’s results are released provide clues to economic conditions for the period in which the results are released. This idea is at the heart of our exclusive surprise prediction model – the Zacks Earnings ESP (Expected Surprise Prediction).

Zacks Earnings ESP compares the most accurate estimate to Zacks’ consensus estimate for the quarter; most accurate estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts who revise their estimates just before the results are released have the latest information, which could potentially be more accurate than they and other consensus contributors predicted earlier.

Thus, a positive or negative ESP reading of earnings theoretically indicates the likely deviation of actual earnings from the consensus estimate. However, the predictive power of the model is only significant for positive ESP readings.

A positive ESP on earnings is a good predictor of a pace of earnings, especially when combined with a Zacks # 1 (strong buy), 2 (buy), or 3 (hold) ranking. Our research shows that stocks with this combination produce positive surprise almost 70% of the time, and a strong Zacks rank actually increases the predictive power of ESP for earnings.

Please note that a negative ESP reading of earnings is not indicative of a shortfall. Our research shows that it is difficult to predict a profit beat with any degree of confidence for stocks with negative earnings ESP readings and / or a Zacks ranking of 4 (sell) or 5 (strong sell).

How have the figures evolved for prestige brands?

For premium brands, the most accurate estimate is the same as Zacks ‘consensus estimate, suggesting that there are no recent analysts’ opinions that differ from what has been considered. to derive the consensus estimate. This resulted in an ESP on earnings of 0%.

On the flip side, the action currently carries a Zacks rank of # 3.

Thus, this combination makes it difficult to conclusively predict that Prestige Brands will beat the consensus EPS estimate.

Does the history of earnings surprises contain a clue?

When calculating estimates of a company’s future earnings, analysts often consider how well it has been able to match past consensus estimates. So it’s worth taking a look at the surprise history to gauge its influence on the upcoming issue.

For the last quarter published, Prestige Brands was expected to post a profit of $ 0.86 per share when it actually made a profit of $ 1.14, offering a surprise of + 32.56%.

In the past four quarters, the company has beaten consensus EPS estimates three times.

Final result

A beat or failure in profits may not be the only basis for a stock to move higher or lower. Many stocks end up losing ground despite declining earnings due to other factors that disappoint investors. Likewise, unforeseen catalysts help a number of stocks win despite a shortfall.

That said, betting on stocks that are expected to exceed profit expectations increases the chances of success. That’s why it’s worth checking out a company’s ESP results and Zacks rankings ahead of its quarterly release. Be sure to use our ESP Earnings Filter to uncover the best stocks to buy or sell before they get published.

Prestige Brands does not appear to be a compelling candidate in terms of earnings. However, investors should also pay attention to other factors when betting on this stock or staying on the sidelines before its results are released.

Bitcoin, like the internet itself, could change everything

Blockchain and cryptocurrency have sparked one of the most exciting talking points in a generation. Some call it “the internet of money” and predict that it could change the way money works forever. If this is true, it could do to banks what Netflix did to Blockbuster and Amazon to Sears. Experts agree that we are in the early stages of this technology and as it develops it will create several investment opportunities.

Zacks just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and other cryptocurrencies with much less volatility than buying them directly.

See 3 Crypto Related Stocks Now >>

Click to get this free report

Prestige Consumer Healthcare Inc. (PBH): Free Inventory Analysis Report

To read this article on Zacks.com, click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link

]]>
https://clomipheneqb.com/prestige-brands-pbh-profits-expected-to-increase-should-you-buy/feed/ 0
4 Common Prescription Drugs Have the Power to Reverse Alzheimer’s Symptoms https://clomipheneqb.com/4-common-prescription-drugs-have-the-power-to-reverse-alzheimers-symptoms/ https://clomipheneqb.com/4-common-prescription-drugs-have-the-power-to-reverse-alzheimers-symptoms/#respond Thu, 28 Oct 2021 16:09:17 +0000 https://clomipheneqb.com/4-common-prescription-drugs-have-the-power-to-reverse-alzheimers-symptoms/

Barcelona, ​​Spain – Currently, there is no drug that can cure Alzheimer’s disease, the most common form of dementia. As research to find an effective new treatment continues, a new study finds that a group of prescription drugs already approved for use can reverse the impact of the disease.

In a study on mice, scientists at IRB Barcelona found that two nonsteroidal anti-inflammatory drugs (NSAIDs) and two blood pressure medications can reverse cognitive impairment caused by Alzheimer’s disease. The drugs also reduced the amount of harmful plaques building up in the hippocampus of the brain and partially restored genes linked to the disease.

In addition to finding a group of existing drugs that prevent mental decline, the team also identified three distinct stages of Alzheimer’s disease – the initial, middle, and late stages. At each stage, the researchers analyzed the behavior of the mice, studying the impact of Alzheimer’s disease on the brain, particularly in the hippocampus. From there, they measured gene expression and protein levels, which build up and form disruptive plaques in patients with dementia.

“What we have observed is that although Alzheimer’s disease shares some characteristics of accelerated aging, it is also affected by totally different aging processes”, explains Dr Patrick Aloy, head of the bioinformatics laboratory. structure and biology of IRB Barcelona networks, in a press release. .

“This disease is caused by the abnormal accumulation of certain proteins, and we have seen that in some cases this is not caused by overproduction but by an error in their elimination.”

What prescriptions can help the brain?

The study authors used a computer tool to find existing drugs on the market today that can reverse cognitive damage at the cellular level. After compiling a list of possible candidates, they tested the drugs on mice with the degenerative disease.

Four drugs were ultimately successful in reversing Alzheimer’s disease and stopping its symptoms in mice. The two NSAIDs are dexketoprofen and etodolac and the two antihypertensives are penbutolol and bendroflumethiazide.

“Epidemiological studies already indicated that people who take anti-inflammatory drugs regularly have a lower incidence of Alzheimer’s disease, but this had not been correlated with a specific drug or mechanism. The results we are publishing are most promising and we hope that further research can be carried out on them as they could lead to a paradigm shift in the treatment of this disease, ”adds Dr Aloy.

In addition to finding these new treatment pathways, researchers say identifying the distinct phases of Alzheimer’s disease is key to early detection. Early diagnosis of the disease will allow doctors to treat patients before the brain damage becomes too severe.

Results appear in the journal Genome medicine.

Source link

]]>
https://clomipheneqb.com/4-common-prescription-drugs-have-the-power-to-reverse-alzheimers-symptoms/feed/ 0